# A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

> **NCT04060888** · PHASE3 · WITHDRAWN · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** Ustekinumab (approximately 6 mg/kg)
- **DRUG:** Ustekinumab 90 milligram (mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04060888
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07-14
- **Primary completion:** 2022-01-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Pre-planned IA (global study) showed lack of efficacy in this indication. No new safety signals observed, findings consistent with known profile.
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04060888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04060888, "A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04060888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*